BioPlus Acquisition Corp.

Acquisition Criteria

BIOS Acquisition Criteria

Disease Area & Geography

Disease agnostic, focused on US, EU, Israel and Australasia(1)

Clear Market Opportunity

Drugs must address a significant unmet need that also represents meaningful commercial opportunities

Strong Management Team

Strong management team with key elements in place

Step Changes in Value Inflection

Multiple clinical study readouts in 18-24 months

Development Stage

Strong preclinical or clinical data driving confidence in successful clinical proof of concept

Scientific Fundamentals

High potential to generate a differentiated therapeutic approach that will alter or significantly enhance the treatment paradigm for stakeholders

(1)Excluding China, Hong Kong and Macau.